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In a prospective cohort study, a close to two-fold elevated risk of bladder cancer was found among men reporting a history of
gonorrhoea (relative risk¼1.92, 95% CI¼1.10–3.33). Our finding warrants further examination of the role of gonorrhoea in bladder
carcinogenesis.
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Bladder cancer is the fourth most common cancer in men, and the
sixth most commonly diagnosed cancer in the US (Ries et al,
2006). Schistosomiasis is a well-established risk factor for bladder
cancer and explains high rates of bladder cancer in regions where
schistosomiasis is endemic; in these regions, squamous cell
carcinoma is the most common histologic subtype (Mostafa
et al, 1999). To date, it remains unclear whether infection and/or
inflammation play a role in bladder carcinogenesis in developed
countries where transitional cell carcinoma is the most common
histologic type.
Gonorrhoea is the second commonest sexually transmitted
disease in the US (CDC, 2005). Infection by the bacterium Neisseria
gonorrhoeae commonly presents as acute urethritis in men,
whereas in women, it initiates in the uterine cervix and is often
asymptomatic (Edwards and Apicella, 2004). Urethritis among
men with gonorrhoea frequently recurs, even after initial treatment
(Bowie, 1990), often causing recurring inflammation of the
urethra. The inflammation caused by such infection may play a
role in bladder carcinogenesis, and two case–control studies have
reported increased bladder cancer risk associated with a history of
gonorrhoea: in one, invasive transitional cell carcinoma showed a
relative risk (RR) of 2.1 (95% CI¼1.0–4.5), after adjusting for age,
sex, and smoking (La Vecchia et al, 1991), and in the other,
bladder cancer RR was 2.42 (95% CI¼1.00–5.83), after adjusting
for age and geographic location (91.5% of cases being invasive)
(Mommsen and Sell, 1983). Because both studies assessed
exposure after the diagnosis of bladder cancer, recall or selection
bias cannot be ruled out as possible explanations for the observed
findings.
We examined the possible role of gonorrhoeal infection in
bladder cancer, while minimising possible bias in a prospective
cohort study of men.
MATERIALS AND METHODS
Study population
The Health Professionals Follow-Up Study was initiated in
1986, when 51529 predominantly white men aged 40–75 years
and living in all 50 US states answered a detailed mailed
questionnaire on medical history, diet and other characteristics.
Deaths of cohort members are frequently reported by
family members or by the postal service in response to
questionnaire mailings. In addition, the National Death Index is
searched biennially for non-respondents; this method has been
shown to have a sensitivity of 98% (Rich-Edwards et al, 1994).
Through 2002, the total follow-up rate for this cohort is greater
than 96%.
At baseline, and biennially thereafter, participants provided
information on their current smoking status, medical conditions,
and other characteristics. The baseline questionnaire included
detailed information on past smoking habits, time since quitting,
and average cigarettes smoked per day by decade.
This study was approved by the Human Subjects Committee of
the Harvard School of Public Health.
History of gonorrhoea
On the 1992 questionnaire, participants were first asked whether
they had ever had a diagnosis of gonorrhoea or syphilis, or neither.
A total of 3212 men (8.7%) did not respond to this specific
question. Information on urinary tract infections (UTI) was
not obtained from participants in this cohort. Prevalence of
syphilis was too low to examine association with bladder cancer in
this study.
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We confirmed self-reported diagnosis of bladder cancer with
medical records (87% of cases). When permission to obtain
medical records was denied, we confirmed the self-reported cancer
and date of diagnosis from a secondary source (e.g., death
certificate or physician). If the primary cause of death reported by
the National Death Index was a previously unreported bladder
cancer, we contacted family members to obtain permission to
retrieve medical records, or at least, to confirm the diagnosis.
Based on pathology reports, over 95% of bladder cancer cases were
transitional cell carcinomas. We used the TNM classification
system to stage the tumours. In a subanalysis, noninvasive
papillary carcinomas (Ta) were separated from invasive tumours
(T1–T4). Carcinoma in situ tumours (Tis) were included in the
overall analysis as these lesions have a high risk of progressing
(Dorkin et al, 1997), but were excluded from the subanalysis (as
they have invasive potential). Overall, 286 incident bladder cancer
cases with complete reported information on gonorrhoea were
available for the analysis.
Statistical analysis
For this analysis, we included 37012 cohort participants who
responded to the 1992 questionnaire and were alive and free of
cancer (except nonmelanoma skin cancer) in 1992. We computed
person-time of follow-up for each participant from the return date
of the 1992 questionnaire to the date of bladder cancer diagnosis,
death from any cause or 31 January 2002, whichever came first. We
categorised participants according to history of gonorrhoea and
included a missing category. We used Cox proportional hazards
models to adjust for potential confounding variables, including age
(5-year categories), pack-years of smoking, current smoking
status, race, and region of residence. Analyses were conducted
using SAS release 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Participants who reported a history of gonorrhoea were slightly
younger, more likely to be ever smokers, and more likely to be
African-American than those with no history of infection.
Participants who responded to the 1992 questionnaire but did
not answer the STD question were similar to men with no history
of infections across baseline characteristics, including indicators of
medical care utilisation, with the exception that they were slightly
older (Supplementary Data).
Men with a history of gonorrhoea had a two-fold increase in
bladder cancer risk compared to men without a history of
gonorrhoea (Table 1). Controlling for smoking history, race,
region of residence, and total fluid intake attenuated the
association slightly (RR¼1.92, 95% CI¼1.10–3.33). In a second-
ary analysis, the association between gonorrhoea and bladder
cancer was slightly stronger after excluding the first 2 years (1992–
1994) of follow-up (multivariable RR¼2.07, 95% CI¼1.19–3.60).
We stratified cases by tumour invasiveness to further examine
the possibility that detection bias is responsible for the observed
association. The association was not apparent in men with
superficial bladder cancer (Ta; Table 1) and was weak among
those with less advanced disease (Ta and T1; RR¼1.14, 95%
CI¼0.50–2.59). It was stronger in men with invasive (T1–T4;
Table 1) and advanced cases only (T2–T4; RR¼4.07, 95%
CI¼1.35–12.3). Further restricting the analysis to invasive TCC
resulted in similar results (RR¼2.38, 95% CI¼1.00–5.63).
The association with gonorrhoea appeared stronger among ever
smokers, although the interaction was not statistically significant
(p-interaction¼0.14). Compared to never smokers without a
history of gonorrhoea, ever smokers without a history of
gonorrhoea had an RR of 2.19 (95% CI¼1.66–2.89), never
smokers with a history of gonorrhoea had an RR of 1.45 (95%
CI¼0.35–6.04), and ever smokers with a history of gonorrhoea
had an RR of 4.84 (95% CI¼2.58–9.07). The association with
gonorrhoea was similar among ever smokers with less than 25
pack-years of smoking (RR¼1.91, 95% CI¼0.87–4.18, yes vs no
history of gonorrhoea) and among men with 25þ pack-years of
smoking (RR¼2.32, 95% CI¼0.95–5.68, yes vs no history).
DISCUSSION
In this prospective study, we observed a two-fold increase in
bladder cancer risk among men with a history of gonorrhoea. The
association was stronger for invasive and advanced bladder cancer
and among current smokers.
Chronic or recurring urinary infections may increase bladder
cancer risk through inflammation or urinary stasis. Urinary tract
infections have been associated with bladder cancer risk in many
case–control studies (Howe et al, 1980; Kantor et al, 1984; Claude
et al, 1986; Piper et al, 1986; Gonzalez et al, 1991; La Vecchia et al,
1991). In one study, increased risk was observed among
individuals who reported their first UTI 15 or more years before
diagnosis (OR¼2.3, 95% CI¼1.0–5.2) (La Vecchia et al, 1991). In
another case–control study, associations with UTI were strongest
for advanced cancers (OR¼4.6, 95% CI¼2.4–8.9) (Kantor et al,
1984).
Lower urinary tract symptoms include incomplete bladder
emptying, frequency, intermittency, urgency, and hesitancy, and
we recently reported a positive association between history of
Table 1 Relative risks of bladder cancer according to history of gonorrhoea (overall and stratified by stage at initial diagnosis) in the Health Professionals
Follow-up Study, 1992–2002
History of gonorrhoea No. of cases Person-years RR
a (95% CI) MV RR
b (95% CI)
No 272 307159 1.0 1.0
Yes 14 9239 2.07 (1.19–3.57) 1.92 (1.10–3.33)*
Among noninvasive (Stage 0a) tumours
c
No 130 306033 1.0 1.0
Yes 3 9166 0.89 (0.28–2.84) 0.87 (0.27–2.77)
Among invasive (Stage 1+) tumours
No 99 305748 1.0 1.0
Yes 7 9182 2.82 (1.28–6.19) 2.42 (1.09–5.38)
w
aAge-adjusted relative risks; 95% CI¼95% confidence intervals.
bMultivariable relative risks (MV RR) from proportional hazard models adjusting for age, pack-years of smoking,
current smoking status, region, total fluid intake, and race.
cNoninvasive in situ (Stage 0is) tumours were excluded as these are typically more aggressive than the noninvasive
papillary tumours. Cases with missing stage were excluded (n¼57). *P-value¼0.02;
wP-value¼0.03.
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ygonorrhoea and such symptoms in this cohort (RR¼1.63, 95%
CI¼1.14–2.33) (Sutcliffe et al, 2005). Based on these findings,
gonorrhoeal infections, generally acquired relatively early in
adulthood, may have a long-lasting impact on bladder function.
It is plausible therefore that the inflammation producing these
urinary symptoms, or increased urinary stasis from incomplete
bladder emptying, or a combination of these could be involved in
bladder carcinogenesis.
Although the interaction with smoking was not statistically
significant in the current study, we observed a strong association
with gonorrhoea and bladder cancer among ever smokers. The
strength of the association among individuals with a high or a low
pack-year smoking history was similar, suggesting that residual
confounding by number of pack-years was unlikely. Effect
modification by smoking of the UTI and bladder cancer
association has been reported in two studies (Kantor et al, 1984;
La Vecchia et al, 1991). In one, when compared to never smokers
with no history of UTI, ever smokers with a history of UTI had an
RR of 10.3 (95% CI¼5.3–20.1), never smokers with a history of
UTI had an RR of 3.2 (95% CI¼1.6–6.3), and ever smokers with
no history of UTI had an RR of 2.4 (95% CI¼1.6–3.6) (La Vecchia
et al, 1991).
The strengths of this study include its prospective design, which
precludes recall bias, a large number of bladder cancer cases, and
high follow-up rates. In addition, we conducted secondary analyses
to address potential biases that may have occurred. We explored
the possibility that a person with a history of gonorrhoea might
be more likely to get a medical work-up that would lead to
the detection of bladder cancer. If detection bias was present, we
would expect less advanced or noninvasive tumours to be more
commonly reported among those with a history of gonorrhoea.
However, we observed stronger associations between gonorrhoea
and bladder cancer risk among those who had advanced or
invasive disease and no association among those with noninvasive
disease. Furthermore, the association strengthened after removing
the first 2 years of follow-up, suggesting that detection bias or
reverse causation is unlikely to explain our findings.
As with other STDs, under reporting is probable, especially in
face-to-face interviews where individuals may be uncomfortable
reporting a positive history. Our data on gonorrhoea was obtained
from mailed questionnaires and fewer than 9% of participants did
not answer that question; we do not know why these men did not
respond, but it is unlikely that nonrespondents were all positive for
gonorrhoea. In this cohort, 2.9% of men reported a history of
gonorrhoea, which is slightly higher than the prevalence rate
reported in a case–control study on STD and prostate cancer
among white men (2.5%) (Hayes et al, 2000). If all nonrespondents
were positive, the prevalence of gonorrhoea would be 11% in this
educated population of health professionals, which is unlikely.
Furthermore, nonrespondents were similar to men with no history
of gonorrhoea with respect to behavioural characteristics. There-
fore, although we cannot rule out the possibility that some
nonrespondents had gonorrhoea, it is unlikely to be a large
proportion, and results would only be biased if the relationship
between gonorrhoea and bladder cancer was different in
responders and nonresponders.
In this cohort study of men, a history of gonorrhoea was
associated with a statistically significant increase in bladder cancer
risk (P-value¼0.02). The 2.4-fold increase in risk observed for
invasive disease and the lack of association among men with
superficial disease suggest that detection bias is unlikely to explain
our observation. Our findings from a prospective study confirm
those of two previous case–control studies and warrant further
study of the role of gonorrhoea and inflammation in bladder
carcinogenesis.
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